Benzinga | Oct 20, 2021 07:11AM EDT

BeyondSpring Announces New Patient-Derived Cancer Model Data For Plinabulin Monotherpy At The AACR-NCI-EORTC Virtual International Conference

* Plinabulin's anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC70 of 35 nM

* The preclinical data is consistent with clinical data in SCLC: plinabulin, in combination with nivolumab and ipilimumab, shows a 46% objective response rate (ORR) in 13 evaluable patients with PD-1/PD-L1 na?ve or resistant tumors in 2nd line and beyond in SCLC